Your session is about to expire
← Back to Search
Interferon
Ingested Interferon Alpha for Type 1 Diabetes
Phase 2
Waitlist Available
Research Sponsored by National Center for Research Resources (NCRR)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing whether a drug called interferon-alpha can prevent type 1 diabetes or at least delay it. Eighty patients with type 1 diabetes will take the drug or a placebo for one year, and researchers will look to see if the drug has any effect on the patient's disease.
Who is the study for?
This trial is for individuals newly diagnosed with type 1 diabetes within the last month, aged between 3 and 25 years old. It's not suitable for those with a history of alcoholism, kidney, heart or lung diseases, impaired intellectual functioning, or on certain medications. Pregnant or nursing individuals are excluded.Check my eligibility
What is being tested?
The study tests if ingested human recombinant interferon-alpha (hrIFN-a) can extend the 'honeymoon' phase in type 1 diabetes where insulin needs drop temporarily. Participants will either receive hrIFN-a or a placebo to assess changes in their C-peptide levels and immune responses over one year.See study design
What are the potential side effects?
Potential side effects may include reactions related to immune system alterations due to interferon-alpha such as flu-like symptoms (fever, chills), fatigue, changes in blood counts affecting immunity and organ function. Specific side effects will be monitored throughout the trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
National Center for Research Resources (NCRR)Lead Sponsor
537 Previous Clinical Trials
317,016 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am either younger than 3 years old or older than 25 years old.I am a young person with type 1 diabetes.I do not have a history of alcoholism, kidney, heart, lung diseases, or intellectual impairments that would prevent me from understanding or participating in the study.I am not taking any immune system affecting drugs like azathioprine or vitamin E.I have abnormal white blood cell counts or am on liver-affecting medication.I was diagnosed with type 1 diabetes within the last month.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does the study accept volunteers of advanced age?
"To be eligible to join this trial, the applicant must have been born after the age of 3 and before 25."
Answered by AI
How does this treatment measure up in terms of risk assessment?
"After careful analysis, our team assigned a rating of 2 to this investigational treatment due the presence of some evidence for its safety but limited data backing up its efficacy."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger